Sanctuary Advisors LLC Sells 1,762 Shares of Medpace Holdings, Inc. $MEDP

Sanctuary Advisors LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 50.3% during the first quarter, HoldingsChannel.com reports. The fund owned 1,742 shares of the company’s stock after selling 1,762 shares during the quarter. Sanctuary Advisors LLC’s holdings in Medpace were worth $836,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace in the 4th quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the 4th quarter worth $30,000. Quarry LP purchased a new stake in shares of Medpace in the 3rd quarter worth $35,000. Finally, Bayban bought a new position in shares of Medpace during the 4th quarter worth $44,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.7%

Medpace stock opened at $601.38 on Friday. The business has a fifty day moving average of $492.09 and a two-hundred day moving average of $494.49. The firm has a market cap of $17.18 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.93 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the firm earned $3.10 EPS. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the topic of several research reports. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Truist Financial raised their target price on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $560.92.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.